Bluebird, at risk of default, agrees to take-private deal
The pioneering gene therapy developer will be acquired by investment firms Carlyle Group and SK Capital for a fraction of what it was once worth.
3 Stocks Estimated To Be Trading At Discounts Of Up To 49.9%
As global markets continue to navigate the complexities of rising inflation and shifting trade policies, U.S. stock indexes are climbing toward record highs, with growth stocks outperforming value ...